Products developed by Theratechnologies target unmet medical needs in commercially attractive specialty markets.

NEWS AND EVENTS

From August 24 to 28, 2004

18th International Diabetes Federation Congress, Paris, France

Presentation by Dr. Thierry Abribat, Ph.D., Vice President and Chief Scientific Officer

TH9507, a Growth Hormone-Releasing Factor Analogue (GRF), does Not Impair Overall Glucose Control and Decreases Non-HDL Cholesterol in Patients With Type 2 Diabetes (PDF : 62.67 K)